Actinium Pharmaceuticals reported $53.39M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Actinium Pharmaceuticals USD 53.39M 6.54M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Bioline Rx USD 7.91M 725K Sep/2025
Capricor Therapeutics USD 19.51M 3.73M Sep/2025
Pfizer USD 1.34B 295M Sep/2025